Eli Lilly stock rises, Novo Nordisk shares jump on potential Medicare coverage
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
BTIG Reiterates Buy Rating on Hims and Hers (HIMS), PT $85
August 5, 2025 9:32 AM EDTBTIG analyst David Larsen reiterated a Buy rating and $85.00 price target on Hims and Hers (NYSE: HIMS).
The analyst comments " On Monday, AMC, HIMS reported 2Q:25 results. Revenue of $544.8M +73% y/y was behind BTIG / consensus of $560.9M / $552M though adjusted EBITDA of $82.2M was well ahead of BTIG / consensus of $80.4M / $73M. Excluding several increases in costs related to hiring new talent, EBITDA would have been closer to ~$90M. Relative to our model, the... More
Hims and Hers (HIMS) PT Raised to $43 at Leerink Partners
August 5, 2025 6:36 AM EDTLeerink Partners analyst Michael Cherny raised the price target on Hims and Hers (NYSE: HIMS) to $43.00 (from $42.00) while maintaining a Market Perform rating.
The analyst comments "Bottom Line: HIMS appears to be in somewhat of a transitory stage, with the companys first revenue miss driven by both the sequential (expected) decline in GLP-1 revenue and the sequential (unexpected) decline in core revenue outside of GLP-1s. We... More
